Needham Reiterates Buy on Ocular Therapeutix, Maintains $20 Price Target

Benzinga · 1d ago
Needham analyst Serge Belanger reiterates Ocular Therapeutix (NASDAQ:OCUL) with a Buy and maintains $20 price target.